ArticleJournal of thrombosis and haemostasis : JTH2019
Increased urokinase and consumption of α
Article in Journal of thrombosis and haemostasis : JTH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.Journal of thrombosis and haemostasis : JTH · 2023Guideline
- Red Blood Cells and Tranexamic Acid in the Inhibition of Fibrinolysis.Seminars in thrombosis and hemostasis · 2026Review
- A novel biosensor for measuring plasmin activity.Research and practice in thrombosis and haemostasis · 2026Article
- Double-edged sword: flavivirus NS1 enhances human plasmin-mediated fibrinolysis while being targeted for cleavage and inactivation.The Journal of general virology · 2026Article
- Can drug-induced platelet dysfunction be reversed?Research and practice in thrombosis and haemostasis · 2026Review
- M1 protein from group ABlood vessels, thrombosis & hemostasis · 2025Article
- Plasminogen activation and plasmin activity are not necessary to prevent venous thrombosis/thromboembolism.Blood · 2025Observational
- Multivalent Tranexamic Acid (TXA) and Benzamidine Derivatives for Serine Protease Inhibition.ACS pharmacology & translational science · 2025Article
- Tranexamic acid for haemostasis and beyond: does dose matter?Thrombosis journal · 2023Review
- The efficacy of tranexamic acid treatment with different time and doses for traumatic brain injury: a systematic review and meta-analysis.Thrombosis journal · 2022Article
- A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.Advanced healthcare materials · 2022Article
- Tranexamic acid alters the immunophenotype of phagocytes after lower limb surgery.Thrombosis journal · 2022Article
- Is it possible to make a common reference standard for D-dimer measurements? Communication from the ISTH SSC Subcommittee on Fibrinolysis.Journal of thrombosis and haemostasis : JTH · 2022Article
- Tranexamic Acid Is Not a Universal Hemostatic Agent.HemaSphere · 2021Article
- Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.Science advances · 2021Article
- Article
- Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.Blood advances · 2019Article
- Increased urokinase and consumption of αJournal of thrombosis and haemostasis : JTH · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Essentials Delayed treatment with tranexamic acid results in loss of efficacy and poor outcomes. Increasing urokinase activity may account for adverse effects of late tranexamic acid treatment. Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting. α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.